Design, synthesis, and biological activity evaluation of a series of pleuromutilin derivatives with novel C14 side chains. 2020

Yun-Ge Li, and Ju-Xian Wang, and Guo-Ning Zhang, and Mei Zhu, and Xue-Fu You, and Yu-Cheng Wang, and Fan Zhang
School of Pharmacy, Jinzhou Medical University, Jinzhou 121001, PR China.

In this work, according to the 'me-too me-better' design strategy, a peculiar side chain different from lefamulin at C14 position of pleuromutilin was introduced. A series of novel thioether pleuromutilin derivatives containing cyclohexane in the C14 chain was synthesized by ten-step synthesis reaction. All derivatives were characterized by Nuclear Magnetic Resonance (NMR) and High Resolution Mass Spectrometer (HRMS). Furthermore, majority of derivatives displayed moderate antibacterial activity in vitro. However, the compound 2C and 2J exhibited comparable or superior antibacterial activity to lefamulin. The summarized structure-activity relationship not only made the variety of pleuromutilin derivatives more diverse, but also provided new ideas for its design and development.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011083 Polycyclic Compounds Compounds which contain two or more rings in their structure. Compounds, Polycyclic
D004224 Diterpenes Twenty-carbon compounds derived from MEVALONIC ACID or deoxyxylulose phosphate. Diterpene,Diterpenes, Cembrane,Diterpenes, Labdane,Diterpenoid,Labdane Diterpene,Norditerpene,Norditerpenes,Norditerpenoid,Cembranes,Diterpenoids,Labdanes,Norditerpenoids,Cembrane Diterpenes,Diterpene, Labdane,Labdane Diterpenes
D000097567 Pleuromutilins A tricyclic diterpene natural product isolated from Pleurotus mutilus (now referred to as Clitopilus scyphoides). Possesses modest antibacterial activity against primarily gram-positive bacterial organisms. Octahydro-5,8-dihydroxy-4,6,9,10- tetramethyl-6-vinyl-3a,9-propano-3aH-cyclopenta- cycloocten-1(4H)-one 8-glycolate,Pleuromutilin,Pleuromutilin Antibiotics,Drosophilin B
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013212 Staphylococcus epidermidis A species of STAPHYLOCOCCUS that is a spherical, non-motile, gram-positive, chemoorganotrophic, facultative anaerobe. Mainly found on the skin and mucous membrane of warm-blooded animals, it can be primary pathogen or secondary invader.
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D055624 Methicillin-Resistant Staphylococcus aureus A strain of Staphylococcus aureus that is non-susceptible to the action of METHICILLIN. The mechanism of resistance usually involves modification of normal or the presence of acquired PENICILLIN BINDING PROTEINS. MRSA,Methicillin Resistant Staphylococcus aureus

Related Publications

Yun-Ge Li, and Ju-Xian Wang, and Guo-Ning Zhang, and Mei Zhu, and Xue-Fu You, and Yu-Cheng Wang, and Fan Zhang
October 2022, Chemical biology & drug design,
Yun-Ge Li, and Ju-Xian Wang, and Guo-Ning Zhang, and Mei Zhu, and Xue-Fu You, and Yu-Cheng Wang, and Fan Zhang
June 2017, Molecules (Basel, Switzerland),
Yun-Ge Li, and Ju-Xian Wang, and Guo-Ning Zhang, and Mei Zhu, and Xue-Fu You, and Yu-Cheng Wang, and Fan Zhang
January 2017, Biological & pharmaceutical bulletin,
Yun-Ge Li, and Ju-Xian Wang, and Guo-Ning Zhang, and Mei Zhu, and Xue-Fu You, and Yu-Cheng Wang, and Fan Zhang
November 2019, European journal of medicinal chemistry,
Yun-Ge Li, and Ju-Xian Wang, and Guo-Ning Zhang, and Mei Zhu, and Xue-Fu You, and Yu-Cheng Wang, and Fan Zhang
December 2020, Bioorganic chemistry,
Yun-Ge Li, and Ju-Xian Wang, and Guo-Ning Zhang, and Mei Zhu, and Xue-Fu You, and Yu-Cheng Wang, and Fan Zhang
December 2020, European journal of medicinal chemistry,
Yun-Ge Li, and Ju-Xian Wang, and Guo-Ning Zhang, and Mei Zhu, and Xue-Fu You, and Yu-Cheng Wang, and Fan Zhang
June 2023, Drug development research,
Yun-Ge Li, and Ju-Xian Wang, and Guo-Ning Zhang, and Mei Zhu, and Xue-Fu You, and Yu-Cheng Wang, and Fan Zhang
April 2022, Bioorganic & medicinal chemistry,
Yun-Ge Li, and Ju-Xian Wang, and Guo-Ning Zhang, and Mei Zhu, and Xue-Fu You, and Yu-Cheng Wang, and Fan Zhang
June 2024, Chemical biology & drug design,
Yun-Ge Li, and Ju-Xian Wang, and Guo-Ning Zhang, and Mei Zhu, and Xue-Fu You, and Yu-Cheng Wang, and Fan Zhang
November 2023, Drug development research,
Copied contents to your clipboard!